Checkpoint Therapeutics (NASDAQ:CKPT) Announces Earnings Results

Checkpoint Therapeutics (NASDAQ:CKPT) posted its earnings results on Tuesday. The company reported ($0.23) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.15) by ($0.08), Zacks reports.

Checkpoint Therapeutics Trading Up 4.4 %

Shares of CKPT traded up $0.16 during trading hours on Thursday, reaching $3.78. 1,078,127 shares of the company’s stock traded hands, compared to its average volume of 521,595. The stock has a market cap of $170.17 million, a PE ratio of -2.05 and a beta of 1.23. Checkpoint Therapeutics has a 12 month low of $1.36 and a 12 month high of $3.97. The firm’s 50 day simple moving average is $2.79 and its 200-day simple moving average is $2.33.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reissued a “buy” rating and set a $20.00 target price on shares of Checkpoint Therapeutics in a research report on Thursday.

Checkpoint Therapeutics Company Profile

Checkpoint Therapeutics, Inc, a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors.